ABUS Arbutus Biopharma CorpcompanySEC Filings & Insider Trading Activity 2026
Latest Arbutus Biopharma Corp (ABUS) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on March 23, 2026, a 10-Q quarterly report filed on November 13, 2025, an 8-K current report filed on April 15, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for Arbutus Biopharma Corp (ABUS) (SEC CIK 1447028), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 8-K Current Report AnalysisRecent 8-K Filings
Item 8.01: Other Events
- • Arbutus and partner Genevant entered a Settlement Agreement, announced March 3, 2026 — nature, terms, and financial impact disclosed only via Exhibit 99.1
- • Settlement agreements typically resolve patent/licensing disputes; material to ABUS given its LNP (lipid nanoparticle) IP monetization strategy
Item 1.01: Entry into a Material Definitive Agreement
- • Moderna to pay $950M noncontingent lump sum to Arbutus/Genevant on or before July 8, 2026, resolving all LNP patent litigation
- • Additional $1.3B contingent payment triggered if Federal Circuit affirms rejection of Moderna's §1498 defense; prorated if only partial win; repayable with interest if victory later overturned
Recent 8-K FilingsCurrent Reports
AI-powered analysis of Arbutus Biopharma Corp (ABUS) 8-K current reports disclosing material events.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Apr 15, 2026 | — | — | — |
10-K | Mar 23, 2026 | Dec 31, 2025 | — | |
8-K | Mar 23, 2026 | — | — | — |
8-K | Mar 3, 2026 | — | Analysis | — |
8-K | Feb 20, 2026 | — | — | |
8-K | Feb 6, 2026 | — | — | |
8-K | Jan 16, 2026 | — | — | |
8-K | Dec 11, 2025 | — | — | |
10-Q | Nov 13, 2025 | Sep 30, 2025 | — | |
10-Q | Aug 6, 2025 | Jun 30, 2025 | — | |
10-Q | May 14, 2025 | Mar 31, 2025 | — | |
10-K | Mar 27, 2025 | Dec 31, 2024 | — | |
10-Q | Nov 6, 2024 | Sep 30, 2024 | — | |
10-Q | Aug 8, 2024 | Jun 30, 2024 | — | |
10-Q | May 2, 2024 | Mar 31, 2024 | — | |
10-K | Mar 5, 2024 | Dec 31, 2023 | — | |
10-Q | Nov 7, 2023 | Sep 30, 2023 | — | |
10-Q | Aug 3, 2023 | Jun 30, 2023 | — | |
10-Q | May 4, 2023 | Mar 31, 2023 | — | |
10-K | Mar 2, 2023 | Dec 31, 2022 | — | |
10-Q | Nov 9, 2022 | Sep 30, 2022 | — | |
10-Q | Aug 4, 2022 | Jun 30, 2022 | — | |
10-Q | May 5, 2022 | Mar 31, 2022 | — | |
10-K | Mar 3, 2022 | Dec 31, 2021 | — | |
10-Q | Nov 4, 2021 | Sep 30, 2021 | — |
Frequently Asked Questions
What are the latest ABUS SEC filings in 2026?
Arbutus Biopharma Corp (ABUS) has filed a 10-K annual report on March 23, 2026, a 10-Q quarterly report on November 13, 2025, an 8-K current report on April 15, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did ABUS file its most recent 10-K annual report?
Arbutus Biopharma Corp (ABUS) filed its most recent 10-K annual report on March 23, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view ABUS 10-Q quarterly reports?
Arbutus Biopharma Corp (ABUS)'s most recent 10-Q quarterly report was filed on November 13, 2025. SignalX displays every ABUS 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has ABUS filed recently?
Arbutus Biopharma Corp (ABUS)'s most recent 8-K was filed on April 15, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find ABUS insider trading activity (Form 4)?
SignalX aggregates every ABUS Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does ABUS file with the SEC?
Arbutus Biopharma Corp (ABUS) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new ABUS filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Arbutus Biopharma Corp (ABUS).
What is ABUS's SEC CIK number?
Arbutus Biopharma Corp (ABUS)'s SEC CIK (Central Index Key) number is 1447028. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1447028 to look up all ABUS filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find ABUS return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from Arbutus Biopharma Corp (ABUS) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of Arbutus Biopharma Corp SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 59+ filings.